Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology BOSTON and NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount...

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...